SCHEMBL5118520

SCHEMBL5118520

COC1Oc2c(c(=O)oc3cc(C)c(Cl)cc23)C1c1c(O)c2cc(Cl)c(C)cc2oc1=O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSNK2A2 P19784 1/20 0.38
CSNK2B P67870 1/20 0.38
CSNK2A1 P68400 1/20 0.38
NQO1 P15559 6/20 0.37
MCL1 Q07820 1/20 0.34
KMT2A Q03164 2/20 0.34
KDM4E B2RXH2 3/20 0.33
GAA P10253 3/20 0.33
MAOB P27338 2/20 0.33
GLA P06280 2/20 0.33
GFER P55789 1/20 0.33
ALDH1A1 P00352 3/20 0.32
TSHR P16473 1/20 0.32
LMNA P02545 2/20 0.32
HSD17B10 Q99714 2/20 0.32
MEN1 O00255 1/20 0.32
MAPT P10636 1/20 0.32
CASP1 P29466 1/20 0.32
CASP7 P55210 1/20 0.32
HSD17B3 P37058 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5117858 0.91 NQO1 (0.46) CSNK2A2CSNK2BCSNK2A1NQO1MCL1
SCHEMBL5341461 0.85 NQO1 (0.39) CSNK2A2CSNK2BCSNK2A1NQO1MCL1
SCHEMBL5115207 0.83 NQO1 (0.47) CSNK2A2CSNK2BCSNK2A1NQO1KDM4E
SCHEMBL5126126 0.82 NQO1 (0.48) CSNK2A2CSNK2BCSNK2A1NQO1KMT2A
SCHEMBL5118767 0.81 HSD17B3 (0.37) NQO1MCL1KDM4EGAAMAOB
SCHEMBL5124909 0.81 NQO1 (0.37) NQO1KDM4EMAOBALDH1A1LMNA
SCHEMBL5125229 0.81 PRNP (0.42) CSNK2A2CSNK2BCSNK2A1NQO1KMT2A
SCHEMBL5125433 0.80 NQO1 (0.38) CSNK2A2CSNK2BCSNK2A1NQO1KMT2A
SCHEMBL5120361 0.79 NQO1 (0.53) CSNK2A2CSNK2BCSNK2A1NQO1KMT2A
SCHEMBL5120322 0.79 NQO1 (0.46) NQO1KMT2AKDM4EGAAGLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7384975-B2 Substituted furochromenes, preparation thereof and their antiinflammatory action GLAXOSMITHKLINE ISTRAZIVACKI CENTAR ZAGREB D.O.O. (HR) 2008-06-10 US disclosed
US-20060148889-A1 Substituted furochromenes, preparation thereof and their antiinflammatory action PLIVA-ISTRAZIVACKI INSTITUT D.O.O. (HR) 2006-07-06 US disclosed
EP-1648902-A1 SUBSTITUTED FUROCHROMENES, PREPARATION THEREOF AND THEIR ANTIINFLAMMATORY ACTION PLIVA-ISTRAZIVACKI INSTITUT d.o.o. (HR) 2006-04-26 EP disclosed
WO-2005010007-A1 SUBSTITUTED FUROCHROMENES, PREPARATION THEREOF AND THEIR ANTIINFLAMMATORY ACTION PLIVA- ISTRAZIVACKI INSTITUT D.O.O. (HR) 2005-02-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060148889-A1 Substituted furochromenes, preparation thereof and their antiinflammatory action CYP11B2, CYP11B1, LTC4S CSNK2A2 886/4885CSNK2B 767/4885CSNK2A1 799/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.